ERBB2 and neoplasm: In HER2-positive breast cancer mice, tumor growth was almost completely inhibited by trastuzumab treatment (13/17); however, the tumor-suppressive capability of trastuzumab was significantly reduced in hormonal mice lacking FcγR III (1/15).